Renowned Parkinson’s Expert Prof. Olivier Rascol Appointed to Lead NeuraLight’s Scientific Advisory Board

We are honored to welcome Prof. Olivier Rascol, a globally recognized leader in neurology, as the new Head of NeuraLight’s Scientific Advisory Board

Prof. Rascol brings over three decades of leadership in Parkinson’s disease clinical research, with deep expertise in motor progression, disease modification, and clinical trial design. As Professor of Clinical Pharmacology at Toulouse University Hospital and a long-standing contributor to pivotal global studies, his work has helped shape how progression is measured and how treatments are evaluated in neurodegenerative diseases.

At NeuraLight, Prof. Rascol will guide our scientific strategy and help expand the clinical utility of our platform as we continue scaling our precision eye movement-based biomarkers across therapeutic areas.

“NeuraLight’s biomarkers have the potential to dramatically improve how we track progression in neurological diseases,” said Prof. Olivier Rascol. “By detecting meaningful changes more objectively, we can design smarter trials, reduce patient burden, and accelerate the path to effective therapies.”

This appointment reinforces our commitment to enhancing the efficiency and sensitivity of clinical trials through validated, non-invasive, and scalable biomarkers. With Prof. Rascol’s leadership, NeuraLight will further align its platform with regulatory and scientific priorities—supporting drug development programs with tools that accelerate decisions and de-risk trials.

As our biomarkers become increasingly embedded in the endpoint strategies of leading trials, Prof. Rascol’s guidance will ensure our continued scientific excellence, rigor, and real-world impact.